Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kazuo Samizo"'
Publikováno v:
YAKUGAKU ZASSHI. 136:945-950
The promotion of self-medication by pharmacies, with the aim of encouraging a patient's self-selection of proper OTC drug, is written about in the national action plan "Japan is Back". The subject of self-medication has been improved in the 2013 revi
Publikováno v:
Journal of Pharmaceutical Sciences. 102:3447-3450
Drug toxicity impedes drug development and its clinical use. In the present study, a toxicity risk index (TRI), which is an index for warning idiosyncratic drug toxicity (IDT), was proposed. The TRI of drugs was defined as a function of dose, pharmac
Publikováno v:
Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku. 12:1-12
Autor:
Kazuo Samizo, Naoko Nishimura, Tomoko Yoshimura, Takahiro Tamura, Masao Itoh, Yuko Yamazaki, Masami Horiguchi, Chiyoji Ishikura
Publikováno v:
Japanese Journal of Hospital Pharmacy. 24:750-758
Autor:
Sachiko Minegishi, Kazuo Samizo, Kaname Hiramoto, Hideo Ishizuka, Chiyoji Ishikura, Toshimi Iizuka
Publikováno v:
Japanese Journal of Hospital Pharmacy. 24:526-532
Publikováno v:
Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku. 2:69-80
Publikováno v:
Japanese Journal of Hospital Pharmacy. 23:256-262
Publikováno v:
Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku. 1:107-115
Autor:
Shigeru Kageyama, Kazuo Samizo, Yukari Kamijima, Kiyoshi Kubota, Ryozo Nagai, Yoshihiro Shimodozono, Tadashi Kusunoki, Nobuhiro Ooba, Shingo Horiguchi, Mitsunori Yagame
Publikováno v:
Pharmacoepidemiology and drug safety. 17(9)
Purpose In hypertensive patients with diabetes, antihypertensive therapy is important in reducing the risk of macro- and microvascular complications. In contrast to the guidelines issued by the American Diabetes Association (ADA) in and after 2002, t
Autor:
S. Hinotsu, Shigeru Kageyama, Tsugumichi Sato, Chikuma Hamada, Kazuo Samizo, Kiyoshi Kubota, Yasuo Ohashi, Eri Kawabe
Publikováno v:
Drug safety. 25(11)
Introduction: Two pilot studies for prescription-event monitoring in Japan (J-PEM) were launched in 1997 and 1998. Here we present data regarding adverse events that were reported in the second pilot J-PEM study where losartan was compared with ACE i